去甲氧柔红霉素治疗急性髓系白血病的临床观察  

Clinical Observation of Idarubicin in the Treatment of Acute Myeloid Leukemia

作　　者：卢英豪[1] 王季石[1] 方琴[2] 曾小箐[1] 何玲[1] 沈如刚[1] 孙志强[1] 张燕[1] 

机构地区：[1]贵阳医学院附属医院血液科,贵阳市550004 [2]贵阳医学院附属医院药剂科,贵阳市550004

出　　处：《中国药房》2010年第32期3012-3013,共2页China Pharmacy

基　　金：国家自然科学基金资助项目(30760276)

摘　　要：目的:观察去甲氧柔红霉素(IDA)与柔红霉素(DNR)、米托蒽醌(MTN)、吡柔比星(THP)治疗急性髓系白血病的疗效和毒副反应。方法:选择我院2005年4月～2010年4月住院的62例急性髓系白血病患者,随机分为2组,治疗组30例采用IDA+阿糖胞苷(Ara-C)治疗,对照组32例采用DNR(或MTN、THP)+Ara-C治疗。结果:治疗组和对照组完全缓解率(CR)分别为80.0%和43.8%,总有效率(RR)分别为93.3%和68.8%,临床严重感染率分别为36.7%和34.4%。2组CR和RR比较,差异有统计学意义(P<0.05),但2组的严重感染率比较,差异无统计学意义(P>0.05)。结论:以IDA组成的联合化疗方案治疗急性髓系白血病疗效较好。OBJECTIVE： To investigate clinical efficacy and toxic reaction of idarubicin （IDA）, daunorubicin （DNR）, mitoxantrone （MTN） and theprubicine （THP） in the treatment of acute myeloid leukemia. METHODS： 62 patients with acute myeloid leukemia were selected from our hospital during the period of Apr. 2005～Apr. 2010 and randomly divided into 2 groups. Treatment group received IDA and Ara-C （n=30） and control group DNR, MTN or THP combined with Ara-C （n=32）. RESULTS： The complete remission （CR） rates were 80.0% for treatment group and 43.8% for control group. The total effective rates （RR） of treatment group and control group were 93.3% and 68.8%, respectively. The rates of severe infection in the clinic were 36.7% and 34.4%, respectively. There were statistical significances in the difference of CR rate and RR rate between 2 groups （P〈0.05）, while there was no statistical significance in the differences of rate of severe infection between 2 groups （P〉0.05）. CONCLUSION： Combined chemotherapeutic scheme containing IDA have sound effect on the acute myeloid leukemia.

关 键 词：去甲氧柔红霉素 柔红霉素 米托蒽醌 吡柔比星 急性髓系白血病 

分 类 号：R551[医药卫生—血液循环系统疾病] R969[医药卫生—内科学]